---
title: "Ibrance (palbociclib), all indications: Dosing and administration questions"
description: "Dosing and administration questions on Ibrance (palbociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Before treatment, Dosing, Administration, Treatment combinations, and Prescribing. Questions: Is a pregnancy test needed before starting Ibrance? How is the Ibrance dose reduced for side effects? How should the Ibrance dose be adjusted for neutropenia? How should the Ibrance dose be adjusted for non-hematologic side effects? 7 further questions follow. 11 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance/dosing-and-administration"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib), all indications: Dosing and administration questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Before treatment

<a id="ibrance-pregnancy-test"></a>

### Is a pregnancy test needed before starting Ibrance?

> “Females of reproductive potential should have a pregnancy test prior to starting treatment with IBRANCE.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Females%20of%20reproductive%20potential%20should,to%20starting%20treatment%20with%20IBRANCE.)

## Dosing

<a id="ibrance-dose-reductions"></a>

### How is the Ibrance dose reduced for side effects?

> “Modify the dose if needed based on individual safety and tolerability<sup>1,2</sup>”

Source: [IBRANCE: Dose Modifications, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/modifications#:~:text=Modify%20the%20dose%20if%20needed%20based%20on%20individual%20safety%20and)

> “The recommended dose modifications for adverse reactions are listed in Tables 1, 2, and 3.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20recommended%20dose%20modifications%20for,Tables%201%2C%202%2C%20and%203.)

> “Table 1. Recommended Dose Modification for Adverse Reactions
> *
> If further dose reduction below 75 mg/day is required, discontinue.
>
>
>
> Dose Level
>
>
>
> Dose
>
>
>
>
> Recommended starting dose
>
>
>
> 125 mg/day
>
>
>
>
> First dose reduction
>
>
>
> 100 mg/day
>
>
>
>
> Second dose reduction
>
>
>
> 75 mg/day*”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Table%201.%20Recommended%20Dose%20Modification,75%20mg%2Fday%2A)

<a id="ibrance-neutropenia-dose-adjustment"></a>

### How should the Ibrance dose be adjusted for neutropenia?

> “Table 2. Dose Modification and Management – Hematologic Toxicities*
> Grading according to CTCAE 4.0.
> CTCAE=Common Terminology Criteria for Adverse Events; LLN=lower limit of normal.
>
> *
> Table applies to all hematologic adverse reactions except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).
> †
> Absolute neutrophil count (ANC): Grade 1: ANC < LLN – 1500/mm3; Grade 2: ANC 1000 – <1500/mm3; Grade 3: ANC 500 – <1000/mm3; Grade 4: ANC <500/mm3.
>
>
>
> Monitor complete blood counts prior to the start of IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated.
>
>
>
>
>
> For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, monitor complete blood counts for subsequent cycles every 3 months, prior to the beginning of a cycle and as clinically indicated.
>
>
>
>
> CTCAE Grade
>
>
>
> Dose Modifications
>
>
>
>
> Grade 1 or 2
>
>
>
> No dose adjustment is required.
>
>
>
>
> Grade 3
>
>
>
> Day 1 of cycle:
> Withhold IBRANCE, repeat complete blood count monitoring within 1 week. When recovered to Grade ≤2, start the next cycle at the same dose.
>
> Day 15 of first 2 cycles:
> If Grade 3 on Day 15, continue IBRANCE at current dose to complete cycle and repeat complete blood count on Day 22.
> If Grade 4 on Day 22, see Grade 4 dose modification guidelines below.
>
> Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles.
>
>
>
>
> Grade 3 neutropenia† with fever ≥38.5 °C and/or infection
>
>
>
> At any time:
> Withhold IBRANCE until recovery to Grade ≤2.
> Resume at the next lower dose.
>
>
>
>
> Grade 4
>
>
>
> At any time:
> Withhold IBRANCE until recovery to Grade ≤2.
> Resume at the next lower dose.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Table%202.%20Dose%20Modification%20and,Resume%20at%20the%20next%20lower%20dose.)

Note: In the table, each CTCAE grade is followed by its dose modification.

<a id="ibrance-non-hematologic-dose-adjustment"></a>

### How should the Ibrance dose be adjusted for non-hematologic side effects?

> “Table 3. Dose Modification and Management – Non-Hematologic Toxicities
> Grading according to CTCAE 4.0.
> CTCAE=Common Terminology Criteria for Adverse Events.
>
>
> CTCAE Grade
>
>
>
> Dose Modifications
>
>
>
>
> Grade 1 or 2
>
>
>
> No dose adjustment is required.
>
>
>
>
> Grade ≥3 non-hematologic toxicity (if persisting despite optimal medical treatment)
>
>
>
> Withhold until symptoms resolve to:
>
> •
> Grade ≤1;
> •
> Grade ≤2 (if not considered a safety risk for the patient)
>
> Resume at the next lower dose.
>
> Permanently discontinue IBRANCE in patients with severe interstitial lung disease (ILD)/pneumonitis.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Table%203.%20Dose%20Modification%20and,severe%20interstitial%20lung%20disease%20%28ILD%29%2Fpneumonitis.)

<a id="ibrance-missed-dose"></a>

### What if a dose of Ibrance is missed or vomited?

> “If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.”

Source: [IBRANCE: Dosing & Administration, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/administration#:~:text=If%20the%20patient%20vomits%20or,taken%20at%20the%20usual%20time.)

> “If you miss a dose of IBRANCE or vomit after taking a dose of IBRANCE, do not take another dose on that day. Take your next dose at your regular time.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=If%20you%20miss%20a%20dose,dose%20at%20your%20regular%20time.)

## Administration

<a id="ibrance-time-of-day"></a>

### What time of day should Ibrance be taken?

> “Patients should be encouraged to take their dose at approximately the same time each day.”

Source: [IBRANCE: Dosing & Administration, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/administration#:~:text=Patients%20should%20be%20encouraged%20to,the%20same%20time%20each%20day.)

> “Advise patients to take their dose of IBRANCE at approximately the same time each day.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Advise%20patients%20to%20take%20their,the%20same%20time%20each%20day.)

<a id="ibrance-food"></a>

### Should Ibrance tablets or capsules be taken with food?

> “IBRANCE tablets can be taken with or without food. IBRANCE capsules should always be taken with food.”

Source: [IBRANCE: Dosing & Administration, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/administration#:~:text=IBRANCE%20tablets%20can%20be%20taken,always%20be%20taken%20with%20food.)

> “IBRANCE tablet may be taken with or without food”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=IBRANCE%20tablet%20may%20be%20taken%20with%20or%20without%20food)

> “IBRANCE capsule should be taken with food”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191#:~:text=IBRANCE%20capsule%20should%20be%20taken%20with%20food)

Note: The second passage is from the IBRANCE tablets Prescribing Information and the third from the IBRANCE capsules Prescribing Information.

<a id="ibrance-capsules-with-food-reason"></a>

### Why should Ibrance capsules be taken with food?

> “Food effect: Palbociclib absorption and exposure were very low in approximately 13% of the population under the fasted condition. Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent. Therefore, food intake reduced the intersubject variability of palbociclib exposure, which supports administration of IBRANCE with food.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191#:~:text=Food%20effect%3A%20Palbociclib%20absorption%20and,administration%20of%20IBRANCE%20with%20food.)

<a id="ibrance-swallow-whole"></a>

### Can Ibrance tablets or capsules be crushed, split, or opened?

> “IBRANCE capsules and tablets should be swallowed whole (patients should not chew, crush, open, or split them prior to swallowing). Capsules and tablets should not be ingested if they are broken, cracked, or otherwise not intact.”

Source: [IBRANCE: Dosing & Administration, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/administration#:~:text=IBRANCE%20capsules%20and%20tablets%20should,cracked%2C%20or%20otherwise%20not%20intact.)

> “IBRANCE tablets should be swallowed whole (do not chew, crush, or split them prior to swallowing).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=IBRANCE%20tablets%20should%20be%20swallowed,split%20them%20prior%20to%20swallowing%29.)

> “IBRANCE capsules should be swallowed whole (do not chew, crush, or open them prior to swallowing).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191#:~:text=IBRANCE%20capsules%20should%20be%20swallowed,open%20them%20prior%20to%20swallowing%29.)

## Treatment combinations

<a id="ibrance-men-lhrh"></a>

### Should men taking Ibrance receive an LHRH agonist?

> “For men treated with combination IBRANCE plus aromatase inhibitor, IBRANCE plus inavolisib and fulvestrant therapy, or IBRANCE plus trastuzumab, with or without pertuzumab, plus endocrine therapy, consider treatment with an LHRH agonist according to current clinical practice standards.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=For%20men%20treated%20with%20combination,to%20current%20clinical%20practice%20standards.)

Note: The label sentence names each IBRANCE combination regimen, including the inavolisib and trastuzumab regimens.

## Prescribing

<a id="ibrance-prescribing-formulation"></a>

### How should an Ibrance prescription specify tablets or capsules?

> “If the NDC codes are unavailable for selection at your practice, you must specify the dosage and formulation type on all IBRANCE prescriptions.”

Source: [IBRANCE: Tablets & Capsules, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/tablets-capsules#:~:text=If%20the%20NDC%20codes%20are,type%20on%20all%20IBRANCE%20prescriptions.)

## Related pages
- [Medical information: Ibrance (palbociclib): All indications](https://www.evicenter.com/medical-information/ibrance)
- [Indication](https://www.evicenter.com/medical-information/ibrance/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ibrance/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/ibrance/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ibrance/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/ibrance/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ibrance/access-and-coverage)
